Cycloheximide sensitivity of orotic acid biosynthesis induced by ammonia and glycine administration.
Administration of either ammonia or glycine to both rats and mice results in an increased synthesis in the liver and urinary excretion of orotic acid. The two most relevant observations obtained are that carbamoyl phosphate synthesized inside the mitochondria is involved in the increased synthesis of orotic acid and that this latter process is almost completely abolished by cycloheximide and actinomycin D, inhibitors of protein and RNA synthesis. Orotic acid synthesis could be controlled by an induction-suppression mechanism. Inhibition of synthesis of excess orotic acid brought about by N-(phosphonacetyl)-L-aspartic acid but not by acivicin, suggests that glutamine-dependent cytosolic synthesis of carbamoyl phosphate, is not involved. Administration of ornithine together with glycine completely suppressed the synthesis of orotic acid, but promoted a twofold increase of urea excretion. The concentration of ornithine rather than that of carbamoyl phosphate or the activity of the enzymes involved, may represent a limiting factor controlling both the flux of ammonia in the urea cycle and the availability of mitochondrial carbamoyl phosphate for orotic acid synthesis. Two enzymes have been found to be induced by glycine: ornithine decarboxylase and aspartate transcarbamoylase (aspartate carbamoyltransferase). Both enzymes may contribute to the increase in orotic acid synthesis, aspartate transcarbamoylase more directly and ornithine decarboxylase by lowering the ornithine concentration. Ornithine decarboxylase activity was completely suppressed but that of aspartate transcarbamoylase was further increased by cycloheximide treatment. Inhibition of orotic acid biosynthesis by cycloheximide appears to be the result of a decreased availability in the cytosol of carbamoyl phosphate synthesized inside the mitochondria.
Vasudevan
S
S
Department of Pathology, University of Toronto, Canada.
Laconi
E
E
Rao
P M
PM
Rajalakshmi
S
S
Sarma
D S
DS
La Piana
G
G
Fransvea
E
E
Marzulli
D
D
Lofrumento
N E
NE
D000643:Ammonium Chloride / Q000494:pharmacology*; D000818:Animals; D002221:Carbamyl Phosphate / Q000378:metabolism; D003513:Cycloheximide / Q000494:pharmacology*; D003609:Dactinomycin / Q000494:pharmacology; D004790:Enzyme Induction; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005998:Glycine / Q000494:pharmacology*; D007555:Isoxazoles / Q000494:pharmacology; D007700:Kinetics; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008930:Mitochondria, Liver / Q000187:drug effects / Q000378:metabolism*; D008954:Models, Biological; D009955:Ornithine Decarboxylase / Q000096:biosynthesis*; D009963:Orotic Acid / Q000378:metabolism*; D051381:Rats; D011916:Rats, Inbred F344
D004791:Enzyme Inhibitors; D007555:Isoxazoles; D000643:Ammonium Chloride; D003609:Dactinomycin; D002221:Carbamyl Phosphate; D009963:Orotic Acid; D003513:Cycloheximide; D009955:Ornithine Decarboxylase; C006303:acivicin; D005998:Glycine